论文部分内容阅读
肺是曲菌感染的宿主器官,已为大家所熟悉。曲霉菌广泛存在于自然界中,一般不致病,只有当机体抵抗力下降或某些药物不适当应用后,吸入的或经血液循环而来的曲菌孢子在肺内大量生长繁殖,才会导致曲菌感染。肺曲菌病。1729年Micheli发现并命名,1856年Virchow首次描述曲霉菌在人肺的病理情况。该症临床极少见,近年来,由于对本症认识水平及检查手段的提高,同时因大量广谱抗菌素、化疗药物、免疫抑制剂、激素等药物应用,临床报道有明显增多趋势。为正确认识和处理肺曲菌病,本文对该病治疗中的有关问题进行综述。
Lung is the host organ of Aspergillus infection and is familiar to all. Aspergillus widespread in nature, generally not pathogenic, and only when the body resistance decreased or inappropriate use of some drugs, inhalation or blood circulation from aspergillus spores in the lungs to a large number of growth and reproduction, will lead to Aspergillus infection. Pulmonary aspergillosis. Micheli was discovered and named in 1729, and in 1856 Virchow first described the pathology of Aspergillus in the human lung. This disease is extremely rare in clinical practice. In recent years, due to the increased awareness of this disease and the means of examination, clinical reports have been significantly increased due to the large number of broad-spectrum antibiotics, chemotherapy drugs, immunosuppressive agents and hormones. In order to correctly understand and deal with pulmonary aspergillosis, this article reviews the related problems in the treatment of this disease.